RAF Target Anti-Cancer Drug
Hanmi Pharmaceutical Co. (CEOs Kwon Seo-chang and Won Jong-soo) announced on May 5 that they received the approval of a 1st-phase clinical test of the combination therapy of RAF target anti-cancer drug HM95573 of which technology was transferred to Genentech, a subsidiary of Roche from Korea’s Ministry of Food and Drug Safety last year.
The phase 1b clinical trial approved on May 4 is aimed at evaluating safety, tolerability and pharmacokinetics in a therapy which combines Cotellic (Cobimetinib), an MEK target anticancer drug of Genentech, and HM95573.
Clinical trials are conducted on patients with locally advanced or metastatic solid cancers with K-RAS, N-RAS, and B-RAF mutations. More information about the clinical test will not be disclosed according to an agreement between the two companies.
Hanmi Pharmaceutical and Genentech, a subsidiary of Roche, signed a licensing agreement on the development and commercialization of HM95573, an RAF target anti-cancer drug, in September 2016.